A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

NCT06339242 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Furmonertinib

Sponsor

Jiangsu Province Nanjing Brain Hospital